Ace Therapeutics, a preclinical contract research organization (CRO) specializing in analgesic drug development, has announced a comprehensive suite of end-to-end services designed to advance pain therapeutic research. The company's platform covers all stages from target discovery and mechanism verification to pharmacological validation and safety assessment, addressing the complex demands of modern pain drug research.
The core of Ace Therapeutics' offering lies in its extensive portfolio of in vivo pain models for drug testing, which spans nearly all mainstream pain classifications. These include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models. To complement these, the company provides systematic preclinical pain assessment services using well-established methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test, covering mechanical, thermal, chemical, cold, and electrical stimulation pain modalities.
Beyond in vivo models, Ace Therapeutics has developed in vitro neuropathic pain model development services utilizing dorsal root ganglion (DRG) cells, iPSC-derived sensory neurons, and co-culture systems to explore pain-related cellular mechanisms. This integrated approach enhances the translational value of preclinical research, allowing clients to study various physiological pain mechanisms and evaluate compound efficacy.
The company's preclinical analgesic drug development services extend to target-based and modality-based drug discovery, supporting research on G-protein coupled receptors, cytokine networks, and ion channels including voltage-gated channels. These services deliver solutions for small-molecule analgesics, biologics such as antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. Mechanism-driven research covers peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
Ace Therapeutics' full-service pipeline includes target validation, in vitro screening, in vivo pharmacology, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection. For special research needs, the company can design customized pain models and testing assays according to unique drug mechanisms and research objectives.
This announcement underscores the growing demand for specialized preclinical services in pain research, where complex mechanisms and high failure rates necessitate robust, validated platforms. By offering a one-stop solution, Ace Therapeutics aims to streamline the development of novel analgesics and address the significant unmet medical need for effective pain treatments.
